Life Technologies Corporation announces the launch of Lipofectamine® 3000, the company’s most efficient and versatile transfection reagent for nucleic acid delivery in the broadest spectrum of cell lines. The product increases efficiency up to 10-fold in difficult-to-transfect cells, which is key for researchers working with more biologically relevant cell models.
“Its superior transfection efficiency, coupled with the reduction of cytotoxicity-associated cell alteration, provides consistent results and more significant experiments,” said Rui Eduardo Castro, Ph.D., Av. Professor Gama Pinto, University of Lisbon, who studies the pathogenesis of human non-alcoholic liver disease (NAFLD). “This leads simply to better research.”
Working with biologically relevant cell models provides researchers with more meaningful answers to their research questions. The lack of lipid-based transfection products that efficiently transfect these cell types has challenged researchers for many years. To overcome these obstacles, Lipofectamine 3000 is designed to optimize every step in the transfection process and deliver superior...
“The greatest benefit we’ve seen is its versatility. In some cases, it can even replace electroporation, which improves the power of experiments and the ability to make meaningful comparisons,” says Natasha Roark, Scientist, Synthetic Biology, Research and Development at Life Technologies. “Lipofectamine 3000 greatly simplifies my workflow, in part, because the viability that I’ve experienced post transfection has been much better. This allows me to get it right the first time.”
Uma Lakshmipathy, Ph.D., Principal Scientist, Cell Biology at Life Technologies, said: “Lipofectamine 3000 challenges the notion that reagent-based methods are ineffective in delivering large reprogramming vectors by enabling efficient reprogramming of skin fibroblasts with Life Technologies’ Epi5 Episomal iPSC Reprogramming Kit, therefore providing an easier and streamlined workflow for human iPSC generation.”
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
